Novavax (NVAX) Rises But Trails Market: What Investors Should Know

Company Performance - Novavax (NVAX) closed at $8.55, showing a +0.53% change from the previous day's closing price, underperforming compared to the S&P 500's daily gain of 1.83% [1] - Over the past month, Novavax shares have decreased by 5.5%, while the Medical sector and S&P 500 have lost 3.48% and 3.31%, respectively [1] Earnings Expectations - The upcoming earnings report for Novavax is expected to show an EPS of -$ 0.67, which represents a 53.47% increase compared to the same quarter last year [2] - Revenue is forecasted to be $90.72 million, indicating a significant decline of 68.86% compared to the corresponding quarter of the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Novavax are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with 1 stocks historically yielding an average annual return of +25% since 1988 [5] - Novavax currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having increased by 87.5% over the last 30 days [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, ranks in the top 24% of all industries, indicating strong performance potential [6]